Matthias Leisegang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Matthias Leisegang has a total of 157 co-authors. Here are the top co-authors by number of shared publications:
- Steven P. Wolf
Department of Medicine, The University of Chicago, Chicago, Illinois, USA
12 shared publications - Hans Schreiber
Department of Pathology, The University of Chicago, Chicago, IL 60637
11 shared publications - Kazuma Kiyotani
Laboratory of Immunogenomics, Center for Intractable Diseases and ImmunoGenomics (CiDIG), National Institutes of Biomedical Innovation, Health and Nutrition (NIBN), Japan
11 shared publications - Karin Schreiber
David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL, USA
10 shared publications - Boris Engels
Novartis Institutes for BioMedical Research, Cambridge, MA
9 shared publications - Kimberley Drousch
Institute of Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
9 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published by Wiley in HemaSphere
- Vol. 10 (11)
Maladaptive DNA damage responses impair CD8 T‐cell fitness after allogeneic stem cell transplantation
- 4 November 2026
- Published by Wiley in HemaSphere
- Vol. 10 (11)
Open AccessMaladaptive DNA damage responses impair CD8 T‐cell fitness after allogeneic stem cell transplantation
- 4 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF11
TCR Sensitivity Shapes Recognition of Tumor Antigen Presented by Host Cells and TCR T-cell Efficacy in Solid Tumors
Despite advances in adoptive T-cell therapy, therapeutic efficacy in solid tumors remains inconsistent, and the mechanistic determinants of treatment failure are incompletely understood. Increasing evidence suggests that effective antitumor responses depend not only on direct recognition of malignant cells but also on interactions with the tumor microenvironment, including nonmalignant host cells that cross-present tumor antigens. Using an HLA-A2–transgenic syngeneic mouse cancer model that enables near-physiologic presentation of human tumor antigens by both malignant and host cells, we investigated how T-cell receptor (TCR) antigen sensitivity relates to therapeutic outcome. We compared TCR-engineered T cells (TCR T cell) with different antigen sensitivities directed against the same HLA-A2–restricted melanoma antigen. Although high- and low-sensitivity TCR T cells recognized tumor cells comparably in vitro, only high-sensitivity TCR T cells mediated durable tumor regression in vivo. Improved tumor control correlated with enhanced recognition of cross-presented tumor antigens on tumor-associated CD11b+ myeloid cells and increased intratumoral effector activity. Interferon γ levels in tumor tissue and peripheral blood reflected intratumoral T-cell activity and correlated with therapeutic response. Together, these findings identify host cell antigen recognition as a sensitivity-dependent functional correlate of TCR T-cell efficacy and provide a mechanistic explanation for the superior activity of higher-sensitivity TCRs in solid tumors.
- 4 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF11
TCR Sensitivity Shapes Recognition of Tumor Antigen Presented by Host Cells and TCR T-cell Efficacy in Solid Tumors
Despite advances in adoptive T-cell therapy, therapeutic efficacy in solid tumors remains inconsistent, and the mechanistic determinants of treatment failure are incompletely understood. Increasing evidence suggests that effective antitumor responses depend not only on direct recognition of malignant cells but also on interactions with the tumor microenvironment, including nonmalignant host cells that cross-present tumor antigens. Using an HLA-A2–transgenic syngeneic mouse cancer model that enables near-physiologic presentation of human tumor antigens by both malignant and host cells, we investigated how T-cell receptor (TCR) antigen sensitivity relates to therapeutic outcome. We compared TCR-engineered T cells (TCR T cell) with different antigen sensitivities directed against the same HLA-A2–restricted melanoma antigen. Although high- and low-sensitivity TCR T cells recognized tumor cells comparably in vitro, only high-sensitivity TCR T cells mediated durable tumor regression in vivo. Improved tumor control correlated with enhanced recognition of cross-presented tumor antigens on tumor-associated CD11b+ myeloid cells and increased intratumoral effector activity. Interferon γ levels in tumor tissue and peripheral blood reflected intratumoral T-cell activity and correlated with therapeutic response. Together, these findings identify host cell antigen recognition as a sensitivity-dependent functional correlate of TCR T-cell efficacy and provide a mechanistic explanation for the superior activity of higher-sensitivity TCRs in solid tumors.
- Open Access
- 5 March 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (10) , 1058-1069
A CD22-specific T-cell receptor enables effective adoptive T-cell therapy for B-cell malignancies
CD19 chimeric antigen receptor (CAR) T-cell therapy has become the standard of care in relapse and/or refractory B-cell malignancies. Up to 30% to 60% of patients experience relapsed disease because of the emergence of CD19low or CD19− tumor cell clones. Although bispecific CD19/CD22 CAR T cells have been explored, limited persistence and antigen downregulation of CD19 and/or CD22 have compromised their efficacy in relapsing patients. A comprehensive analysis of CD22 expression revealed that CD22 is ubiquitously expressed across all subgroups of B-cell lymphomas and B-cell leukemias, establishing CD22 as a valuable immunotherapeutic target. Using a humanized mouse model with a diverse human T-cell receptor (TCR) repertoire, we identified a high-affinity TCR targeting a CD22 epitope presented by HLA-A∗02:01. In vitro, this TCR demonstrated high specificity and efficacy in both CD22+ cell lines and primary patient-derived tumor samples. Importantly, CD22 TCR T cells outperformed CD22 CAR T cells in recognizing cells with low CD22 surface expression, including CD22low Nalm6 cells that emerged after in vivo CD19 T-cell treatment. Unlike CD22 CAR T cells, CD22 TCR T cells effectively recognized tumor cells that predominantly express intracellular CD22. Notably, in vivo validation in a Nalm6 B-cell leukemia model confirmed the superior activity of CD22 TCR T cells against CD22low cells compared to CD22 CAR T cells. In conclusion, our findings provide strong preclinical evidence supporting CD22 TCR-based therapy as a potent treatment option for CD22low B-cell malignancies, including patients who relapsed after CD19 CAR T-cell therapy.
- 5 March 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (10) , 1058-1069
Open AccessA CD22-specific T-cell receptor enables effective adoptive T-cell therapy for B-cell malignancies
CD19 chimeric antigen receptor (CAR) T-cell therapy has become the standard of care in relapse and/or refractory B-cell malignancies. Up to 30% to 60% of patients experience relapsed disease because of the emergence of CD19low or CD19− tumor cell clones. Although bispecific CD19/CD22 CAR T cells have been explored, limited persistence and antigen downregulation of CD19 and/or CD22 have compromised their efficacy in relapsing patients. A comprehensive analysis of CD22 expression revealed that CD22 is ubiquitously expressed across all subgroups of B-cell lymphomas and B-cell leukemias, establishing CD22 as a valuable immunotherapeutic target. Using a humanized mouse model with a diverse human T-cell receptor (TCR) repertoire, we identified a high-affinity TCR targeting a CD22 epitope presented by HLA-A∗02:01. In vitro, this TCR demonstrated high specificity and efficacy in both CD22+ cell lines and primary patient-derived tumor samples. Importantly, CD22 TCR T cells outperformed CD22 CAR T cells in recognizing cells with low CD22 surface expression, including CD22low Nalm6 cells that emerged after in vivo CD19 T-cell treatment. Unlike CD22 CAR T cells, CD22 TCR T cells effectively recognized tumor cells that predominantly express intracellular CD22. Notably, in vivo validation in a Nalm6 B-cell leukemia model confirmed the superior activity of CD22 TCR T cells against CD22low cells compared to CD22 CAR T cells. In conclusion, our findings provide strong preclinical evidence supporting CD22 TCR-based therapy as a potent treatment option for CD22low B-cell malignancies, including patients who relapsed after CD19 CAR T-cell therapy.
- Open Access
- 14 June 2025
- Published by Taylor & Francis in OncoImmunology
- Vol. 14 (1) , 2514041
Mutant p53-specific CD8TCR-therapy combined with a CD4TCR prevents relapse of cancer and outgrowth of micrometastases
Relapse remains challenging in the treatment of metastatic cancers. More than 50% of human cancers harbor mutant p53 (mp53) as a cancer-specific target. We present the spontaneously metastasizing tumor model Ag104A to advance mp53-specific T cell receptor engineered T cell therapy (TCR-therapy). We identified in Ag104A an autochthonous p53D256E mutation as neoantigen recognized by a TCR isolated from CD8+ T cells (CD8TCR). Cloning of the Ag104A cancer revealed mp53 expression in >99% of cancer cells. Targeting mp53 by CD8TCR-therapy was initially therapeutic, but tumors escaped as cancer cells with reduced or lack of antigen expression. Therefore, we determined whether escape could be prevented by combining the mp53-specific CD8TCR with a CD4+ T cell-derived TCR (CD4TCR) recognizing a mutant antigen presented on the stroma of the cancer. No relapse occurred when the mp53-specific CD8TCR was combined with the stroma-recognizing CD4TCR. The combination therapy also prevented the development of macrometastases from cancer cells that had already spread to the lung at the time of TCR-therapy. Macrometastases were only observed after monotherapy. Thus, in a spontaneously metastatic model, tumor relapse and development of macrometastases can be prevented by combining a CD8TCR targeting an autochthonous p53-mutation with a mutation-specific CD4TCR recognizing tumor stroma.
- 14 June 2025
- Published by Taylor & Francis in OncoImmunology
- Vol. 14 (1) , 2514041
Open AccessMutant p53-specific CD8TCR-therapy combined with a CD4TCR prevents relapse of cancer and outgrowth of micrometastases
Relapse remains challenging in the treatment of metastatic cancers. More than 50% of human cancers harbor mutant p53 (mp53) as a cancer-specific target. We present the spontaneously metastasizing tumor model Ag104A to advance mp53-specific T cell receptor engineered T cell therapy (TCR-therapy). We identified in Ag104A an autochthonous p53D256E mutation as neoantigen recognized by a TCR isolated from CD8+ T cells (CD8TCR). Cloning of the Ag104A cancer revealed mp53 expression in >99% of cancer cells. Targeting mp53 by CD8TCR-therapy was initially therapeutic, but tumors escaped as cancer cells with reduced or lack of antigen expression. Therefore, we determined whether escape could be prevented by combining the mp53-specific CD8TCR with a CD4+ T cell-derived TCR (CD4TCR) recognizing a mutant antigen presented on the stroma of the cancer. No relapse occurred when the mp53-specific CD8TCR was combined with the stroma-recognizing CD4TCR. The combination therapy also prevented the development of macrometastases from cancer cells that had already spread to the lung at the time of TCR-therapy. Macrometastases were only observed after monotherapy. Thus, in a spontaneously metastatic model, tumor relapse and development of macrometastases can be prevented by combining a CD8TCR targeting an autochthonous p53-mutation with a mutation-specific CD4TCR recognizing tumor stroma.
- Open Access
- 2 May 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (5) , e011351
Selection of therapeutically effective T-cell receptors from the diverse tumor-bearing repertoire
Background: The development of T-cell receptor (TCR)-based T-cell therapies is hampered by the difficulties in identifying therapeutically effective tumor-specific TCRs from the natural repertoire of a patient’s cancer-specific T cells. Methods: Here, we mimic experimentally near-patient conditions to analyze the T-cell repertoire in euthymic tumor-bearing mice responding to the H-2K b -presented neoantigen p68 S551F (mp68). We temporarily separated the time point of mp68 expression from that of cancer cell transplantation to exclude the influence of injection-induced inflammation on T-cell priming. Thus, the mp68-specific T-cell response could only develop after the acute inflammatory phase had subsided. Results: We found that mp68-specific TCRs isolated from either tumor-infiltrating T cells or spleens of mice immunized with mp68-expressing cancer cells are diverse and not inherently therapeutic when introduced into peripheral T cells and used for adoptive therapy of established tumors. While measuring short-term T-cell responses in vitro was unreliable for some TCRs in predicting their therapeutic failure, assessing the persistence of cancer cell destruction by TCR-modified T cells in long-term cultures accurately predicted therapeutic outcomes. A tumor-derived TCR with optimal function was also correctly identified with this approach when analyzing human TCRs that recognize the HLA-A2-presented neoantigen CDK4 R24L . Conclusions: We show that a neoantigen-directed T-cell response in tumor-bearing hosts comprises a diverse repertoire. Infiltration and expansion of certain T-cell clonotypes in the tumor do not necessarily correlate with therapeutic efficacy of their TCRs in adoptive therapy. We propose that analysis of persistent rather than immediate responses of TCR-modified T cells in vitro serves as a reliable parameter to identify TCRs that are therapeutically effective in vivo.
- 2 May 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (5) , e011351
Open AccessSelection of therapeutically effective T-cell receptors from the diverse tumor-bearing repertoire
Background: The development of T-cell receptor (TCR)-based T-cell therapies is hampered by the difficulties in identifying therapeutically effective tumor-specific TCRs from the natural repertoire of a patient’s cancer-specific T cells. Methods: Here, we mimic experimentally near-patient conditions to analyze the T-cell repertoire in euthymic tumor-bearing mice responding to the H-2K b -presented neoantigen p68 S551F (mp68). We temporarily separated the time point of mp68 expression from that of cancer cell transplantation to exclude the influence of injection-induced inflammation on T-cell priming. Thus, the mp68-specific T-cell response could only develop after the acute inflammatory phase had subsided. Results: We found that mp68-specific TCRs isolated from either tumor-infiltrating T cells or spleens of mice immunized with mp68-expressing cancer cells are diverse and not inherently therapeutic when introduced into peripheral T cells and used for adoptive therapy of established tumors. While measuring short-term T-cell responses in vitro was unreliable for some TCRs in predicting their therapeutic failure, assessing the persistence of cancer cell destruction by TCR-modified T cells in long-term cultures accurately predicted therapeutic outcomes. A tumor-derived TCR with optimal function was also correctly identified with this approach when analyzing human TCRs that recognize the HLA-A2-presented neoantigen CDK4 R24L . Conclusions: We show that a neoantigen-directed T-cell response in tumor-bearing hosts comprises a diverse repertoire. Infiltration and expansion of certain T-cell clonotypes in the tumor do not necessarily correlate with therapeutic efficacy of their TCRs in adoptive therapy. We propose that analysis of persistent rather than immediate responses of TCR-modified T cells in vitro serves as a reliable parameter to identify TCRs that are therapeutically effective in vivo.
- 13 September 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 9 (99) , eadp6529
CD4 + T cells with convergent TCR recombination reprogram stroma and halt tumor progression in adoptive therapy
Cancers eventually kill hosts even when infiltrated by cancer-specific T cells. We examined whether cancer-specific T cell receptors of CD4 + T cells (CD4TCRs) from tumor-bearing hosts can be exploited for adoptive TCR therapy. We focused on CD4TCRs targeting an autochthonous mutant neoantigen that is only presented by stroma surrounding the MHC class II–negative cancer cells. The 11 most common tetramer-sorted CD4TCRs were tested using TCR-engineered CD4 + T cells. Three TCRs were characterized by convergent recombination for which multiple T cell clonotypes differed in their nucleotide sequences but encoded identical TCR α and β chains. These preferentially selected TCRs destroyed tumors equally well and halted progression through reprogramming of the tumor stroma. TCRs represented by single T cell clonotypes were similarly effective only if they shared CDR elements with preferentially selected TCRs in both α and β chains. Selecting candidate TCRs on the basis of these characteristics can help identify TCRs that are potentially therapeutically effective.
- 13 September 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 9 (99) , eadp6529
CD4 + T cells with convergent TCR recombination reprogram stroma and halt tumor progression in adoptive therapy
Cancers eventually kill hosts even when infiltrated by cancer-specific T cells. We examined whether cancer-specific T cell receptors of CD4 + T cells (CD4TCRs) from tumor-bearing hosts can be exploited for adoptive TCR therapy. We focused on CD4TCRs targeting an autochthonous mutant neoantigen that is only presented by stroma surrounding the MHC class II–negative cancer cells. The 11 most common tetramer-sorted CD4TCRs were tested using TCR-engineered CD4 + T cells. Three TCRs were characterized by convergent recombination for which multiple T cell clonotypes differed in their nucleotide sequences but encoded identical TCR α and β chains. These preferentially selected TCRs destroyed tumors equally well and halted progression through reprogramming of the tumor stroma. TCRs represented by single T cell clonotypes were similarly effective only if they shared CDR elements with preferentially selected TCRs in both α and β chains. Selecting candidate TCRs on the basis of these characteristics can help identify TCRs that are potentially therapeutically effective.
- Open Access
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Video S1 from One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication
Supplementary Video S1 from One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video S1 from One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication
Supplementary Video S1 from One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication
- Open Access
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data1 from One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication
Includes Supplementary Figures 1, 2, 3, 4, 5, 6, 7, 8 and 9. Description of Supplementary Videos S1 and S2. Detailed Supplementary Tables S1, S2 and S3.
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data1 from One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication
Includes Supplementary Figures 1, 2, 3, 4, 5, 6, 7, 8 and 9. Description of Supplementary Videos S1 and S2. Detailed Supplementary Tables S1, S2 and S3.
- Open Access
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Video S2 from One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication
Supplementary Video S2 from One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video S2 from One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication
Supplementary Video S2 from One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication
- Open Access
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Video S2 from One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication
Supplementary Video S2 from One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video S2 from One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication
Supplementary Video S2 from One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication